Novartis Acquires Next-Generation PI3Kα Inhibitor SNV4818 in $3 Billion Deal to Strengthen Breast Cancer Pipeline
核心洞察
Novartis agreed to acquire SNV4818, a pan-mutant-selective PI3Kα (搜索) inhibitor from Synnovation Therapeutics (搜索) for $2 billion upfront plus up to $1 billion in milestones.
The therapy targets PIK3CA mutations found in approximately 40% of HR (搜索)+/HER2 (搜索)- breast cancer patients while sparing healthy cells to improve tolerability.
SNV4818 is currently in Phase 1/2 clinical trials and represents a next-generation approach to address significant unmet medical needs in breast cancer treatment.
Novartis announced it has entered into an agreement with Synnovation Therapeutics (搜索) to acquire SNV4818, a pan-mutant-selective PI3Kα (搜索) inhibitor, for $2 billion upfront and up to $1 billion in milestone payments. The transaction strengthens Novartis' breast cancer pipeline by adding a next-generation therapy designed to target cancer-driving mutations while sparing healthy cells.
The Swiss pharmaceutical company will acquire Pikavation Therapeutics (搜索), a wholly-owned subsidiary of Synnovation that holds the PI3Kα (搜索) inhibitor portfolio including SNV4818. The deal is expected to close in the first half of 2026, subject to customary closing conditions and regulatory approvals.
Targeting a Well-Defined Patient Population
SNV4818 addresses a significant unmet medical need in hormone receptor-positive, human epidermal growth factor receptor two-negative (HR (搜索)+/HER2 (搜索)-) breast cancer. Approximately 40% of HR+/HER2- breast cancer patients have PIK3CA mutations in their tumors, which are associated with worse disease prognosis.
"While mutated PI3Kα (搜索) is a well-established driver in HR (搜索)+/HER2 (搜索)- breast cancer, there remains a challenge in achieving effective pathway inhibition with a tolerable therapeutic profile," said Shreeram Aradhye, M.D., President of Development at Novartis. "SNV4818 applies new mutant-selective chemistry to more precisely target tumor biology while sparing normal cells."
Next-Generation Approach to PI3K Inhibition
The oral drug is currently being evaluated in a Phase 1/2 study for breast cancer and other advanced solid tumors. SNV4818 is designed to selectively target the mutated PI3Kα (搜索) enzyme found in cancer cells while sparing the wild-type PI3Kα in healthy cells, a key differentiator from available PI3Kα inhibitors.
Current PI3Kα (搜索) inhibitors block both mutant and wild-type PI3Kα, leading to tolerability challenges that make it difficult to keep patients on treatment. By focusing specifically on the mutated form in tumors, SNV4818 aims to reduce unwanted side effects, support more consistent dosing, and facilitate combination with hormonal therapy and other treatments earlier in patient care.
Preclinical studies demonstrate strong activity against common PIK3CA mutations and clear selectivity over the normal enzyme, with clinical evaluation ongoing.
Strategic Alignment with Oncology Portfolio
The acquisition supports Novartis' oncology strategy in HR (搜索)+/HER2 (搜索)- breast cancer and fits naturally alongside CDK inhibitors and endocrine therapies as part of potential combination regimens. Aradhye noted that this approach "has the potential to translate proven biology into improved tolerability and more durable benefit for patients through precision medicine."
The biology of mutated PI3Kα (搜索) in HR (搜索)+/HER2 (搜索)- breast cancer is well-understood, making it an attractive target for therapeutic intervention. The program aligns with Novartis' commitment to developing treatments that improve the lives of patients with breast cancer through precision medicine approaches.